Ethical considerations for protecting the options of subjects in primary epidemic vaccine trials
The recent review by Monrad1 presents several issues about secondary vaccine trials. It lays out the case in which a vaccine has been tested through phases I-III and is being deployed. Subsequently (emphasis added), consideration is being given to conducting ‘trials for another vaccine for the patho...
| Authors: | ; |
|---|---|
| Format: | Electronic Article |
| Language: | English |
| Check availability: | HBZ Gateway |
| Journals Online & Print: | Drawer...
|
| Fernleihe: | Fernleihe für die Fachinformationsdienste |
| Published: |
BMJ Publ.
2021
|
| In: |
Journal of medical ethics
Year: 2021, Volume: 47, Issue: 5, Pages: 360 |
| Online Access: |
Volltext (kostenfrei) Volltext (kostenfrei) |
MARC
| LEADER | 00000caa a22000002 4500 | ||
|---|---|---|---|
| 001 | 1816164992 | ||
| 003 | DE-627 | ||
| 005 | 20230428063553.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220908s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/medethics-2020-106851 |2 doi | |
| 035 | |a (DE-627)1816164992 | ||
| 035 | |a (DE-599)KXP1816164992 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 1 |2 ssgn | ||
| 100 | 1 | |a Caplan, L. |e VerfasserIn |4 aut | |
| 245 | 1 | 0 | |a Ethical considerations for protecting the options of subjects in primary epidemic vaccine trials |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The recent review by Monrad1 presents several issues about secondary vaccine trials. It lays out the case in which a vaccine has been tested through phases I-III and is being deployed. Subsequently (emphasis added), consideration is being given to conducting ‘trials for another vaccine for the pathogen’.Monrad states: ‘In summary, we may say that researchers have strong prima facie reasons not to conduct a secondary vaccine trial.’Monrad discusses several factors meriting careful consideration about the need for developing and testing more than one vaccine: relative efficacy, length of immunity, adverse reactions (reactogenicity), ease of storage and administration, economic and logistical factors.What is not addressed are the ethical duties that exist when there are competing phase III vaccine candidates for COVID-19. We have serious concerns about potential ethical inadequacies about these ongoing trials and … | ||
| 700 | 1 | |a Abraham, L. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical ethics |d London : BMJ Publ., 1975 |g 47(2021), 5, Seite 360 |h Online-Ressource |w (DE-627)323607802 |w (DE-600)2026397-1 |w (DE-576)260773972 |x 1473-4257 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2021 |g number:5 |g pages:360 |
| 856 | |u https://jme.bmj.com/content/medethics/47/5/360.full.pdf |x unpaywall |z Vermutlich kostenfreier Zugang |h publisher [open (via free pdf)] | ||
| 856 | 4 | 0 | |u https://doi.org/10.1136/medethics-2020-106851 |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://jme.bmj.com/content/47/5/360.abstract |x Verlag |z kostenfrei |3 Volltext |
| 935 | |a mteo | ||
| 936 | u | w | |d 47 |j 2021 |e 5 |h 360 |
| 951 | |a AR | ||
| ELC | |a 1 | ||
| ITA | |a 1 |t 1 | ||
| LOK | |0 000 xxxxxcx a22 zn 4500 | ||
| LOK | |0 001 4185618948 | ||
| LOK | |0 003 DE-627 | ||
| LOK | |0 004 1816164992 | ||
| LOK | |0 005 20220908053802 | ||
| LOK | |0 008 220908||||||||||||||||ger||||||| | ||
| LOK | |0 035 |a (DE-Tue135)IxTheo#2022-08-03#D34A8A7FA078A24836119559B2AAC872099B48C0 | ||
| LOK | |0 040 |a DE-Tue135 |c DE-627 |d DE-Tue135 | ||
| LOK | |0 092 |o n | ||
| LOK | |0 852 |a DE-Tue135 | ||
| LOK | |0 852 1 |9 00 | ||
| LOK | |0 935 |a ixzs |a ixrk |a zota | ||
| OAS | |a 1 | ||
| ORI | |a SA-MARC-ixtheoa001.raw | ||